JNJ

Business profile & competitive position

Johnson & Johnson is a healthcare holding company operating under the Healthcare sector, specifically the Drug Manufacturers – General industry. Through its subsidiaries, the company employs approximately 138,200 full-time-equivalent people worldwide and runs two business segments: Innovative Medicine and MedTech. Innovative Medicine develops and sells prescription therapeutics in Oncology, Immunology, Neuroscience, Pulmonary Hypertension, Infectious Diseases, and Cardiovascular and Metabolism. MedTech develops products used in cardiovascular, orthopaedics, surgery, and vision procedures. Those products reach retailers, wholesalers, distributors, hospitals, eye-care professionals, and healthcare professionals in virtually all countries of the world.

The financial profile supports the idea that scale and product mix matter here. A net margin of 21.5% and a return on equity of 25.7% sit well above the averages seen across most of the S&P 500, suggesting J&J translates revenue into profit and shareholder returns more efficiently than many large-cap peers. Portfolio concentration is real: DARZALEX/DARZALEX FASPRO accounted for roughly 15.0% of 2025 total revenues, STELARA about 6.5%, and TREMFYA about 5.5%. That concentration in immunology and oncology creates real cash-flow power, but it also means individual franchises can move the needle. The company also faces biosimilar competition against STELARA, which it expects to continue pressuring that franchise. Overall, the margin and ROE figures point to durable pricing power and operational scale rather than a commodity-like business.

Financial posture

At a market capitalization of $654.5 billion, J&J sits among the largest publicly traded healthcare companies. The stock currently trades at a price-to-earnings ratio of 31.4 and a price of $271.6. That P/E is above the long-run historical range for large pharma, though not out of line with the premium the market has assigned to consistently profitable, low-volatility large caps. The net margin of 21.5% reinforces that premium: only a minority of mega-cap healthcare names sustain that level of profitability while also operating a capital-intensive MedTech segment.

Risk-adjusted returns look defensive. The beta is 0.23, implying the stock has moved far less than the overall market on average. Return on equity of 25.7% is robust and suggests equity capital is being reinvested productively. The stock recently closed above its 50-day exponential moving average of $263.21, with an RSI of 57.0, which is neither overbought nor oversold. That combination—a high valuation multiple, low beta, and strong margins—describes a high-quality, income-oriented holding rather than a momentum name.

Strategic priorities & outlook

J&J’s most recent 10-K filing outlines several operational priorities. The most consequential near-term event is the planned separation of the Orthopaedics business, announced in October 2025, with a targeted completion within 18 to 24 months of that announcement. That transaction would reshape the MedTech segment and leave J&J more concentrated in Innovative Medicine plus the remaining MedTech franchises.

The company also emphasizes human capital management built on three pillars: attracting and recruiting top talent, developing and retaining top talent, and empowering and inspiring talent. It references a Credo-based culture of innovation, health, well-being, safety, inclusion, and belonging, and backs that with tools such as J&J Learn and the annual Global Learning Day. On the commercial side, management expects continued global launches of biosimilars against STELARA, which will continue to pressure that brand’s sales. The filing also notes that spending is typically heavier in the fourth quarter, driven mainly by advertising and research and development decisions rather than by meaningful sales seasonality.

Macro & geopolitical exposure

As a Drug Manufacturers – General company with global operations, J&J is exposed to the standard macro and geopolitical risks of the pharmaceutical industry. Drug pricing regulation is a perennial factor: changes to Medicare/Medicaid reimbursement, international reference pricing, or U.S. policy debates around prescription costs can pressure revenue and margins. Regulatory approval and enforcement risks from the FDA and ex-U.S. agencies directly affect launch timelines and commercial certainty.

Intellectual property is another core exposure. Patent cliffs, exclusivity disputes, and the launch of biosimilars and generics can reshape revenue quickly, as the company is already experiencing with STELARA. Global distribution also exposes the business to currency translation, foreign exchange volatility, and cross-border trade policy. Supply chain and manufacturing risks matter for both pharmaceuticals and MedTech, particularly for sterile injectables, biologics, and devices with specialized components. Finally, demographic aging supports long-term demand for healthcare products broadly, but that tailwind does not eliminate pricing, regulatory, or competitive headwinds.

Recent developments

The most recent headline, dated September 21, 2026, from Reuters, reports that J&J’s Caplyta met the main goal of a bipolar mania study. That is a pipeline milestone for the Neuroscience franchise and could be relevant to long-term revenue if approved and commercialized. On September 20, 2026, 247wallst.com included J&J in a list of “3 Dividend Stocks Built for Retirement to Buy in September,” framing the stock as an income-oriented defensive name. Separately, on September 18, 2026, Zacks published “J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?,” and 247wallst.com ran “The Moneymaxxing Crowd Will Love 5 High-Yield Dividend Stocks Under $20.” These headlines generally reflect the market’s recent preference for stable, dividend-paying large caps and the stock’s strong three-month price performance, but they do not by themselves resolve valuation questions.

Earnings behavior & post-earnings drift

J&J has posted a strong earnings track record over the last eight reported quarters, with a beat rate of 7 of 8 and an average earnings surprise of 3.4%. The average 5-day price move after those reports is 0.67%, classified as a positive post-earnings drift. That modest upward drift suggests the market generally digests J&J’s results as slightly better than expected, though the moves are not dramatic.

Looking at the most recent four quarters, the pattern is mixed even though the headline beat rate is high. The July 15, 2026 report delivered EPS of $2.90 versus a $2.84 estimate, a 2.1% surprise, and the stock rose 1.19% the next day and 3.49% over the following five days. The April 14, 2026 quarter also beat, with EPS of $2.70 against $2.68, but the stock fell 0.6% the next day and 5.81% over five days, showing that a narrow beat can still be sold. The January 21, 2026 quarter was exactly in line at $2.46, yet the stock drifted 4.45% higher over five days. The October 14, 2025 report showed EPS of $2.80 versus $2.76, a 1.4% surprise, with a 0.17% next-day move and 0.54% over five days. Next up is the October 13, 2026 report before the open, with a consensus EPS estimate of $2.85.

For a deeper dive, review the full institutional verdict, which aggregates analyst ratings, target ranges, and forward model assumptions beyond the figures covered here.